Roivant Sciences (ROIV) Net Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) Net Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.32 Bn | 197.33 Bn | 7.24 Bn | 802.00 |
| 2 | Gilead Sciences | 181.40 Bn | 178.22 Bn | 6.22 Bn | -16,220.00 |
| 3 | Vertex Pharmaceuticals | 132.36 Bn | 124.51 Bn | 2.84 Bn | -185.00 |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | -763.00 |
| 5 | Argenx Se | 61.64 Bn | 56.46 Bn | 1.37 Bn | 529.00 |
| 6 | Moderna | 54.77 Bn | 49.63 Bn | 52.00 Mn | 4,168.00 |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.83 Bn | 992.69 Mn | 2,208.00 |
| 8 | Biogen | 31.28 Bn | 30.00 Bn | 1.96 Bn | -2,043.00 |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | -753,036.00 |
| 10 | Insmed | 28.16 Bn | 27.00 Bn | 358.27 Mn | 29,636.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -753,036.00 |
| Dec 31, 2025 | -1.28 Mn |
| Sep 30, 2025 | -431,372.00 |
| Jun 30, 2025 | -1.33 Mn |
| Dec 31, 2024 | -2.10 Mn |
| Sep 30, 2024 | 282,141.00 |
| Jun 30, 2024 | 223,564.00 |
| Dec 31, 2023 | 2.38 Mn |
| Sep 30, 2023 | -655,599.00 |
| Jun 30, 2023 | 667,522.00 |
| Dec 31, 2022 | -173,677.00 |
| Sep 30, 2022 | -90,750.00 |
| Jun 30, 2022 | -688,458.00 |
| Dec 31, 2021 | 341,921.00 |
| Sep 30, 2021 | 243,048.00 |
| Jun 30, 2021 | -80,061.00 |